Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC10A1 | Q14973 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 3/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | TOP2A | P11388 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | NT5E | P21589 | 1/20 | 0.34 |
| ▸ | RELA | Q04206 | 1/20 | 0.34 |
| ▸ | PTGES | O14684 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13910945 | 0.93 | CA9 (0.41) | SLC10A1CA9CA1CA2USP2 | |
| SCHEMBL5440871 | 0.93 | CA9 (0.41) | SLC10A1CA9CA1CA2USP2 | |
| SCHEMBL13910930 | 0.86 | SLC10A1 (0.45) | SLC10A1CA9CA1CA2USP2 | |
| SCHEMBL5446514 | 0.85 | TDP1 (0.42) | SLC10A1 | |
| SCHEMBL5448119 | 0.85 | CA9 (0.42) | CA9CA1CA2USP2LMNA | |
| SCHEMBL14374329 | 0.85 | CA9 (0.42) | CA9CA1CA2USP2LMNA | |
| SCHEMBL14374326 | 0.83 | CA9 (0.41) | CA9CA1CA2USP2LMNA | |
| SCHEMBL5454240 | 0.83 | CA9 (0.41) | CA9CA1CA2USP2LMNA | |
| SCHEMBL13910764 | 0.82 | SLC10A1 (0.51) | SLC10A1CA9CA1CA2USP2 | |
| SCHEMBL5443587 | 0.81 | CA9 (0.40) | CA9CA1CA2USP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062243-A1 | Lupane-Type Triterpenoids Modified at 30-Position and Analogues Thereof | ADVANCED LIFE SCIENCES, INC. (US) | 2009-03-05 | — | — | US | disclosed |
| WO-2009020732-A1 | LUPANE-TYPE TRITERPENOIDS MODIFIED AT 30-POSITION AND ANALOGUES THEREOF | ADVANCED LIFE SCIENCES, INC. (US) | 2009-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062243-A1 | Lupane-Type Triterpenoids Modified at 30-Position and Analogues Thereof | BRCA1, PGF, GPER1 | SLC10A1 873/4885CA9 1376/4885CA1 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.